A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer

Introduction BTH1677, a 1,3–1,6 beta-glucan immunomodulator, stimulates a coordinated anti-cancer immune response in combination with anti-tumor antibody therapies. This phase II study explored the efficacy, pharmacokinetics (PK), and safety of BTH1677 combined with cetuximab/carboplatin/paclitaxel...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, M., Sadjadian, P., Kollmeier, J., Lowe, J., Mattson, P., Trout, J. R., Gargano, M., Patchen, M. L., Walsh, R., Beliveau, M., Marier, J. F., Bose, N., Gorden, K., Schneller, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418307/
https://www.ncbi.nlm.nih.gov/pubmed/28303530
http://dx.doi.org/10.1007/s10637-017-0450-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418307/
https://www.ncbi.nlm.nih.gov/pubmed/28303530
http://dx.doi.org/10.1007/s10637-017-0450-3

Ejemplares similares